Global

‡ In these countries please contact our distributor

DURAFIBER

Highly Absorbent Gelling Fibre Dressing

DURAFIBER Gelling Fibre Dressing Range

Om DURAFIBER

DURAFIBER-sortimentet er en ny generation af stærke, non-woven, gelerende fiberbandager, der kan fjernes sammenhængende i ét stykke1-6DURAFIBER, half wet, half dry

Effektive produkter


DURAFIBER-sortimentet er en ny generation af ydedygtige, gelerende fiberbandager, der er fremstillet til at kunne opfylde de mange udfordringer ved inficerede og ikke-inficerede sår med moderat til kraftig væskemængde.


DURAFIBER, der er udviklet med en innovativ fiberteknologi, indeholder en unik non-woven fibersammensætning, der er en essentiel del af produktets egenskaber.

Denne unikke sammensætning giver en unik kombination af fordele, der adskiller DURAFIBER-bandager fra konventionelle gelerende fiberbandager.

 

Fjernes sammenhængende i ét stykke1-6

DURAFIBER Clean one piece removal
Høj vådstyrke og strukturel integritet1-6

  • Lav risiko for fiberfældning og bandagerester3,5
  • Minimal smerte og traume for patienten ved fjernelse af bandagen1-6

Video - teknologien bag DURAFIBER-bandager

 

Effektiv væskekontrol

DURAFIBER Locking In Video Still
Høj absorptions- og retentionskapacitet1,2,4,9

  • Minimal lateral spredning – hjælper med til at beskytte huden omkring såret mod risikoen for maceration2,3,5,8,11 
  • Indkapsler væske og skadelige bakterier – kan hjælpe med til at forhindre risikoen for krydskontamination ved aftagning1,2,4,7-10,12,13

Video - test af lateral spredning

Denne in vitro test illustrerer DURAFIBER-bandagens evne til at indkapsle og absorbere væske og således kontrollere den laterale spredning af sårvæske. 1,2,8 Når DURAFIBER er blevet anbragt, suger det hurtigt væsken væk fra overfladen af petriskålen (som forestiller ekssudatet i sårbunden). Den absorberede væske spredes ikke mod bandagens yderkanter, men holdes inden for området af den simulerede sårbund.
En bandages evne til at kontrollere den laterale spredning af væske er vigtig for at hjælpe med at minimere risikoen for maceration i sårets omgivelser.

 

Video - test af absorbtionsevne

Denne in vitro test anvender væsker med forskellig farve til at illustrere DURAFIBER-bandagens evne til at indkapsle og absorbere væsken, uden at farverne løber ind i hinanden 1,2,7.

Bandagens evne til at absorbere væske er vigtig som en hjælp til at reducere overskydende væske og eventuelle skadelige bakterier fra sårbunden. Dette kan reducere risikoen for krydskontamination ved fjernelse af bandagen.

 

 


Høj patientkomfort 3,5

Skånsom og smidig gelmatrix 1,2,5,19DURAFIBER conforming gel 

  • Hjælper med til at fremme patient komforten3,5
  • Reducerer hulrum, hvor bakterier kan udvikles1,2,12,19,20

Video - test af kontaktflade

Denne in vitro test viser, hvordan DURAFIBER-bandagen hurtigt danner en blød, sammenhængende gel ved kontakt med væske, og former sig efter den simulerede sårbund. Bandagens evne til at opretholde en tæt kontakt med sårets kontaktflade uden at hæfte til såret er væsentlig for at hjælpe med at opretholde et fugtigt sårmiljø, der fremmer sårhelingen. Det hjælper også med at minimere risikoen for ansamling af væske, reducere risikoen for hulrum mellem sår og bandage og minimere risikoen for traume ved fjernelse af bandagen 1,2,12

 

 

 


Bandagens dokumenterede egenskaber

Unikke anti-krympningsegenskaber 1,2,4

  • Minimal krympning i våd tilstand – kan bidrage til vedvarende dækning 1,2,4
  • Opretholder et optimalt, fugtigt sårhelingsmiljø 1,18,21 


Udviklet med innovativ teknologi

DURAFIBER bandagen har en unik, non-woven fibersammensætning, der er en essentiel del af produktets gode egenskaber.

20%

 Naturlige, forstærkende cellulosefibre

+

80%

 Gelerende celluloseethylsulfonatfibre (CES)

=

100%

 Fint spundet matrix, der danner en blød, sammenhængende gel ved kontakt med væske1-6
 

Denne unikke sammensætning giver en eksklusiv kombination af egenskaber, der gør det muligt for DURAFIBER at løse de mange udfordringer ved ekssuderende sår:DURAFIBER animation still

  • Høj styrke i våd tilstand: Cellulosefibre giver den tørre og gelerede matrix indbygget strukturel integritet 1-6
  • Fortræffelig absorptionsevne: Gelerende fibre svulmer op og gelerer ved kontakt med ekssudatet, og absorberer effektivt væsken 1,2,4-6
  • Minimal krympning: Forstærkende fibre opretholder bandagens form i våd tilstand og minimerer krympning 1,2,4
  • Meget smidig: Danner et blødt, sammenhængende gellag, som former sig tæt efter sårbunden 1-3,5,10,14

 

 


Produktinformation om DURAFIBER-bandager

DURAFIBER ALLEVYN Gentle Border Multisite
DURAFIBER ALLEVYN  Gentle Border Multisite

 

ALLEVYN-bandager - et perfekt valg til sekundær fiksering. 28,30 


 

DURAFIBER Ag-bandager

DURAFIBER Ag-bandager er effektive ved infektion

DURAFIBER AgVedvarende frigivelse af sølv i op til 7 dage (in vitro) 14,15

Begynder at dræbe patogener inden for 30 minutters kontakt (in vitro vs. Staphylocuccus aureus, Pseudomonas aeruginosa, MRSA og VRE)16

Giver bredspektret antimikrobiel aktivitet i 4 timer mod patogener (in vitro vs.Pseudomonas aeruginosa, VRE, Bacteroides fragilis, Candida albicans og Rhizopus arrhizus)17


Opretholder antimikrobiel aktivitet i op til 7 dage mod et bredt spektrum af aerobe, anaerobe bakterier, herunder antibiotikaresistente stammer (vist in vitro vs. MRSA, VRE, gær, filamentøse svampepatogener i såret)14,15


Produktinformation om DURAFIBER Ag-bandager
 

Referencer

1 Smith & Nephew Report DS.10.056 R1 05 2010 DURAFIBER Dressing Physical Properties.

2 DS.11.187.DOF Testing Performed as Part of DURAFIBER Photo Shoot.

3 Case Series Evaluation: The Use of DURAFIBER on Exuding Wounds. Wounds UK 2012,Vol 8, No 3.

4 Smith & Nephew Wound Management Laboratory Report Reference DS/10/060/R1, DURAFIBER Ag Dressing Physical Properties, Dowler A, September 2010.

5 Smith & Nephew Wound Management, Data on File Report Reference OR- DOF/28, A prospective, open, multicentre study to evaluate a new fibrous silver dressing in the treatment of moderate to highly exuding chronic wounds, Rafiq G, Fenton S January 2013.

6 Smith & Nephew Wound Management Laboratory Report Reference DS/12/093/DOF, Integrity Testing of DURAFIBER Ag in horse serum and ionic solution, Dowler A, April 2012.

7 Smith & Nephew Wound Management Data on File 10.040.01 April 2010 Visual demonstration of sequestration of Pseudomonas aeruginosa and Staphylococcus aureus in a DURAFIBER dressing using confocal microscopy.

8 Smith & Nephew Report DS.10.042 R1 Report of testing on lateral wicking of DURAFIBER versus AquacelTM and Kaltostat TM dressings.

9 Smith & Nephew Wound Management Laboratory Report Reference DS/12/109/DOF, Testing on Absorption of DURAFIBER Ag versus Aquacel Ag during compression, Dowler A, April 2012.

10 Smith & Nephew Wound Management Laboratory Report Reference DS/12/158/DOF, Sequestration Testing of DURAFIBER Ag, Aquacel Ag and SorbsanTM Silver Flat, Dowler A,June 2012.

11 Smith & Nephew Wound Management Laboratory Report Reference DS/12/108/DOF, Testing on lateral wicking of DURAFIBER Ag versus Aquacel Ag and MaxorbTM Extra Ag dressings, Dowler A, April 2012.

12 Smith & Nephew Research Centre Review Report, The potential for proliferation of bacteria in wound exudate, Report Reference RR-WMP06290-40-01, Woodmansey E, April 2010.

13 Smith & Nephew Wound Management, Data on file report reference 1208007, Visual demonstration of sequestration of Pseudomonas aeruginosa and Staphylococcus aureus in a DURAFIBER Ag dressing using confocal microscopy. Lumb H, August 2012.

14 Smith & Nephew Wound Management, Data on file report reference 1004007, Antimicrobial activity of DURAFIBER Ag and Aquacel Ag against bacteria, yeast and fungi commonly found in wounds over a 7 day period, Woodmansey E, April 2010.

15 Smith & Nephew Wound Management, Data on file report reference 1009012, Antimicrobial activity of DURAFIBER Ag against bacteria, yeast and fungi commonly found in wounds over a 7 day period, Vaughan KL, McMillan J, Lumb H and Woodmansey E, September 2010.

16 Smith & Nephew Wound Management, Data on file report reference 1004009, Assessment of the contact kill activity of DURAFIBER Ag against common wound pathogens, Woodmansey E, April 2010.

17 Smith & Nephew Wound Management, Data on file report reference 1009013, Antimicrobial activity of DURAFIBER Ag against bacteria, yeast and fungi commonly found in wounds over a 4 hour period, Vaughan KL, McMillan J, Lumb H and Woodmansey E, September 2010.

18 World Union of Wound Healing Societies (WUWHS) Principles of best practice. Wound exudate and the role of dressings. A consensus document London MED Ltd. 2007.

19 Smith & Nephew Wound Management Laboratory Report Reference DS/12/143/DOF, Intimate Contact Testing of DURAFIBER Ag, Aquacel Ag and Sorbsan Silver Flat, Dowler A, June 2012.

20 Smith & Nephew Research Centre Review Report RR WMP06290-40-01 The potential for proliferation of bacteria in wound exudate.

21 The Clinical and Physical Properties of DURAFIBER Ag, the Moist Wound Environment and the Autolytic Debridement, Myers D, July 2012.

22 Smith & Nephew Report DS.10.013 R1 02 2010 Aquacel Dressing Physical Properties.

23 Smith & Nephew Wound Management Laboratory Report Reference DS/10/060/R2, Aquacel Ag Dressing Physical Properties.

24 NHS Drug Tariff August 2012 http://www.ppa.org.uk/ppa/edit_intro.htm

25 Unit costs of health and social care, Curtis, L. PSSRU: 2010.

26 Siddiqui AR, Bernstein JM (2010).

27 DURAFIBER Technology video

28 Smith & Nephew Report DS/12/314 R December 2012 Wound Model Testing of DURAFIBER with various secondary dressings

29 DURAFIBER SMTL report 3303 Wound Dressing Testing

30 Smith & Nephew Report Development Services, Analytical Report Reference DS/10/053/R1, Wound Model Testing of DURFAIBER Ag and Aquacel Ag dressings with various secondary dressings, Dowler A, August 2010.

*In comparison with standard Aquacel dressings, excludes Aquacel Ribbon with strengthening fibre and Aquacel Extra

**In comparison with standard Aquacel Ag dressings, excludes Aquacel Ag Ribbon with strengthening fibre and Aquacel Ag Extra

Aquacel is a trademark of Convatec

TM All trademarks acknowledged

Fordele for patienten

Indledning

DURAFIBER-sortimentet er en ny generation af højt absorberende non-woven, gelerende fiberbandager med en ny fiberteknologi og en unik sammensætning.1,2,4,9

DURAFIBER-bandager responderer på kontakt med ekssudatet ved at danne en blød, sammenhængende gel, som hurtigt absorberer overskydende ekssudat, indkapsler den absorberede sårvæske og eventuelle bakterier, og former sig tæt mod sårbunden. 1,2,3-5,7,8,10,14

  • Høj styrke og strukturel integritet i våd tilstand – fjernes sammenhængende i ét stykke 1-6
  • Høj absorptions- og retentionsevne – effektiv væskekontrol 1-6,9
  • Unikke anti-krympningsegenskaber – optimal effektivitet af bandagen 1,2,4
  • Blødhed og smidighed – høj patientkomfort 1,2,3,5

 

  • De følgende in-vitro tests demontrerer tydeligt DURAFIBER bandagens forskellige egenskaber.

Nedenfor finder du en kort beskrivelse af hver test samt et videoklip, der viser resultatet.

Contact Test2 

This in vitro experiment shows how the DURAFIBER dressing rapidly transforms into a soft cohesive gel as it is hydrated with fluid and conforms intimately to the simulated wound bed. The ability of a dressing to maintain close contact with the wound surface without adhering is key in helping to maintain a moist wound environment favourable for healing. It also helps to minimise the risk of pooling; reduce the potential for dead space between the wound and dressing interface and minimise the potential for trauma on dressing removal 1,2,12>

Locking In Test2 

This in vitro experiment uses different coloured fluids to illustrate the ability of DURAFIBER dressings to lock in the fluid it absorbs with the result that there is no bleeding of the colours into one another1,2,7.

The ability of a dressing to lock in fluid is important for helping to remove excess fluid and any harmful bacteria it contains away from the wound bed and may reduce the risk of cross contamination on dressing removal.

Lateral Wicking Test2 

This in vitro experiment illustrates the ability of DURAFIBER dressings to lock in absorbed fluid and so control the lateral spread of wound fluid. 1,2,8

Once applied, DURAFIBER rapidly wicks the fluid away from the surface of the petri dish, (representative of exudate in a wound bed). The absorbed fluid does not spread to the outer edges of the dressing but is contained within the area of the simulated wound bed.

The ability of a dressing to control the lateral spread of fluid is important in helping to minimise the risk of peri-wound maceration.

Absorbency and Shrinkage Test2 

This in vitro experiment demonstrates the ability of DURAFIBER dressings to absorb markedly more fluid and to shrink noticeably less compared to standard Aquacel™*1,2,15

Both DURAFIBER and Aquacel*1,2,15 dressings have 25ml of fluid added to them. The excess fluid that they haven't absorbed is measured and compared in a test tube. The shrinkage seen with each dressing is measured by comparing the original dry and gelled dressing size.

Dressing absorbency is important for ensuring effective fluid management and minimal dressing shrinkage is important for achieving sustained wound bed coverage. 

Dressing Integrity and Gelled Strength Test2 

This in vitro experiment demonstrates the markedly greater gelled strength and integrity of DURAFIBER dressings compared to Aquacel™*1,2,15.

Each dressing has fluid added to the middle of the dressing to simulate the absorption of dressing exudate. Weights are then attached to each dressing until breaking point is reached. The weight required to break the two dressings is measured and compared.

Dressing strength is important for ensuring one piece dressing removal and low risk of dressing residue.5

 

  DURAFIBER-bandager DURAFIBER Ag-bandager

Høj geleret styrke og strukturel integritet  og fjernes sammenhængende i ét stykke1-6

"virkede godt og var meget nem at fjerne og forblev i ét stykke3"

"blev fjernet som et enkelt stykke, og efterlod ingen rester i >95 %  tilfælde5

Fortræffelig absorptionsevne giver effektiv væskekontrol og minimal risiko for  maceration omkring såret 1-6,8,9,11

"påviste fremragende væskekontrol og var effektiv til at kontrollere sårekssudatet3

"blev bedømt som klinisk acceptabelt til ekssudatkontrol i 95,8 % af tilfældene5

Minimal bandagekrympning giver vedvarende dækning og optimal effektivitet af bandagen 1,2,4

“fortsatte med at vise en meget god evne til at forme sig efter sårbunden3

“patienterne havde bandagen på i gennemsnitligt 6,4 dage5

Blød og meget smidig giver høj patientkomfort 1,2,3,5 

“patientkomforten blev bedømt som fortræffelig3

“Komfortabel ved brug i 94,8 % af tilfældene5

 

DURAFIBER Clinical Evidence

Author Title Outcome  
Barrett S
Callaghan R
Ivins N
Stephen -Haynes J
Case series evaluation:
the use of Durafiber on
exuding wounds
Simon Barrett, Rosie Callaghan, Nicky Ivins and Professor Jackie Stephen-Haynes have completed a case series evaluating the use of the new DURAFIBER(Smith&Nephew) dressing on a total of ten patients with a range of wound aetiologies.

The case studies showed that DURAFIBER has the capability to contain high levels of exudate, provide comfort for patients during wear, and on removal as a result of its unique gelled structure and ability to remain intact.

PDF
(1.5MB)

 

 

Author Title Outcome  
Milne J A clinical evaluation of DURAFIBER, a new generation of fibrous gelling dressings "The majority of clinicians rated the performance of DURAFIBER as being either excellent or very good" for ease of dressing application, exudate handling ability, dressing conformability and ease of dressing removal. PDF (122 KB)

 

Evidence Graph

 

Summary of clinician feedback on DURAFIBER in-use performance

 

Case Study

Author Title Outcome  

Murray S, Pardoe A.

Case study of DURAFIBER on a dehisced surgical wound

DURAFIBER in situDURAFIBER achieved “complete healing in four weeks” with the ileostomy reversed.

 

DURAFIBER in situ

PDF (1.4MB)

 

 

Case Study

Author Title Outcome  

Grothier L

A case study illustrating the clinical benefits of using a fibrous gelling dressing

The “wound exudate had been managed effectively being contained within the DURAFIBER dressing with no shrinkage observed.”

PDF (412 KB)

 

 

DURAFIBER Ag

A prospective, open, multi centre study to evaluate a new fibrous silver dressing in the treatment of moderate to highly exuding chronic wounds5.

Ease of Use Graph

Ease of Use

  • The fibrous silver dressing Rated as clinically acceptable for the indication in 100% of patients     
  • Clinicians satisfied with the exudate handling of the fibrous silver dressing in 95.8% of the assessments
  • Easy to apply at 100% of assessments
  • Removed as a single piece in 96.8% of removals
  • No pain on application at 95.8% of assessments
  • No pain on removal at 88.4% of assessments
  • Mean wear time of 6.4 Days

 

Clinical Outcomes

Graph
50% of wounds healed by week 8

 

Graph

There was significant evidence of a reduction in the presence of clinical wound infection between baseline and weeks 4 (p<0.001) and week 8 (p<0.001).

 

Graph

There was also significant evidence of a reduction in the presence of clinical signs of infection between baseline and weeks 4 (p=0.002) and 8 (p<0.001).

 

Graph

The median percentage reduction in wound dimensions between baseline and study completion and the resulting median percentage reduction per week were as follows: Area 98.2% (12.9% per week), Depth 100% (12.7% per week) 

 

References

1 Smith & Nephew Report DS.10.056 R1 05 2010 DURAFIBER Dressing Physical Properties.

2 DS.11.187.DOF Testing Performed as Part of DURAFIBER Photo Shoot.

3 Case Series Evaluation: The Use of DURAFIBER on Exuding Wounds. Wounds UK 2012,Vol 8, No 3.

4 Smith & Nephew Wound Management Laboratory Report Reference DS/10/060/R1, DURAFIBER Ag Dressing Physical Properties, Dowler A, September 2010.

5 Smith & Nephew Wound Management, Data on File Report Reference OR- DOF/28, A prospective, open, multicentre study to evaluate a new fibrous silver dressing in the treatment of moderate to highly exuding chronic wounds, Rafiq G, Fenton S January 2013.

6 Smith & Nephew Wound Management Laboratory Report Reference DS/12/093/DOF, Integrity Testing of DURAFIBER Ag in horse serum and ionic solution, Dowler A, April 2012.

7 Smith & Nephew Wound Management Data on File 10.040.01 April 2010 Visual demonstration of sequestration of Pseudomonas aeruginosa and Staphylococcus aureus in a DURAFIBER dressing using confocal microscopy.

8 Smith & Nephew Report DS.10.042 R1 Report of testing on lateral wicking of DURAFIBER versus AquacelTM and Kaltostat TM dressings.

9 Smith & Nephew Wound Management Laboratory Report Reference DS/12/109/DOF, Testing on Absorption of DURAFIBER Ag versus Aquacel Ag during compression, Dowler A, April 2012.

10 Smith & Nephew Wound Management Laboratory Report Reference DS/12/158/DOF, Sequestration Testing of DURAFIBER Ag, Aquacel Ag and SorbsanTM Silver Flat, Dowler A,June 2012.

11 Smith & Nephew Wound Management Laboratory Report Reference DS/12/108/DOF, Testing on lateral wicking of DURAFIBER Ag versus Aquacel Ag and MaxorbTM Extra Ag dressings, Dowler A, April 2012.

12 Smith & Nephew Research Centre Review Report, The potential for proliferation of bacteria in wound exudate, Report Reference RR-WMP06290-40-01, Woodmansey E, April 2010.

13 Smith & Nephew Wound Management, Data on file report reference 1208007, Visual demonstration of sequestration of Pseudomonas aeruginosa and Staphylococcus aureus in a DURAFIBER Ag dressing using confocal microscopy. Lumb H, August 2012.

14 Smith & Nephew Wound Management, Data on file report reference 1004007, Antimicrobial activity of DURAFIBER Ag and Aquacel Ag against bacteria, yeast and fungi commonly found in wounds over a 7 day period, Woodmansey E, April 2010.

15 Smith & Nephew Wound Management, Data on file report reference 1009012, Antimicrobial activity of DURAFIBER Ag against bacteria, yeast and fungi commonly found in wounds over a 7 day period, Vaughan KL, McMillan J, Lumb H and Woodmansey E, September 2010.

16 Smith & Nephew Wound Management, Data on file report reference 1004009, Assessment of the contact kill activity of DURAFIBER Ag against common wound pathogens, Woodmansey E, April 2010.

17 Smith & Nephew Wound Management, Data on file report reference 1009013, Antimicrobial activity of DURAFIBER Ag against bacteria, yeast and fungi commonly found in wounds over a 4 hour period, Vaughan KL, McMillan J, Lumb H and Woodmansey E, September 2010.

18 World Union of Wound Healing Societies (WUWHS) Principles of best practice. Wound exudate and the role of dressings. A consensus document London MED Ltd. 2007.

19 Smith & Nephew Wound Management Laboratory Report Reference DS/12/143/DOF, Intimate Contact Testing of DURAFIBER Ag, Aquacel Ag and Sorbsan Silver Flat, Dowler A, June 2012.

20 Smith & Nephew Research Centre Review Report RR WMP06290-40-01 The potential for proliferation of bacteria in wound exudate.

21 The Clinical and Physical Properties of DURAFIBER Ag, the Moist Wound Environment and the Autolytic Debridement, Myers D, July 2012.

22 Smith & Nephew Report DS.10.013 R1 02 2010 Aquacel Dressing Physical Properties.

23 Smith & Nephew Wound Management Laboratory Report Reference DS/10/060/R2, Aquacel Ag Dressing Physical Properties.

24 NHS Drug Tariff August 2012 http://www.ppa.org.uk/ppa/edit_intro.htm

25 Unit costs of health and social care, Curtis, L. PSSRU: 2010.

26 Siddiqui AR, Bernstein JM (2010).

27 DURAFIBER Technology video

28 Smith & Nephew Report DS/12/314 R December 2012 Wound Model Testing of DURAFIBER with various secondary dressings

29 DURAFIBER SMTL report 3303 Wound Dressing Testing

30 Smith & Nephew Report Development Services, Analytical Report Reference DS/10/053/R1, Wound Model Testing of DURFAIBER Ag and Aquacel Ag dressings with various secondary dressings, Dowler A, August 2010.

*In comparison with standard Aquacel dressings, excludes Aquacel Ribbon with strengthening fibre and Aquacel Extra

**In comparison with standard Aquacel Ag dressings, excludes Aquacel Ag Ribbon with strengthening fibre and Aquacel Ag Extra

Aquacel is a trademark of Convatec

TM All trademarks acknowledged

References relate to in vitro testing excluding references 3,5,18,21,24,25,26

Økonomiske fordele


Skånsom for budgettet 1-6

Med de unikke fibersammensætninger giver DURAFIBER-bandager en kombination af kliniske fordele, der både understøtter patienten og budgettet.

Kan fjernes i ét stykke1-6

Minimal tid, sygeplejersken skal bruge på bandageskift 24,25   DURAFIBER Dressing range
     
Effektiv væskekontrol 1-6,9

Op til 7 dages bæretid
     
Komfortabel gelmatrix med minimal krympning 1-5,19

Fremmer optimal effektivitet af bandagen og tilpasning til patienten 3,5 
Langvarig antimikrobiel aktivitet (in vitro)14,15

>

Kan reducere de forbundne infektionsomkostninger 5,26

Kliniske case-studier af DURAFIBER's egenskaber kan fås på anmodning.

 

Referencer

1 Smith & Nephew Report DS.10.056 R1 05 2010 DURAFIBER Dressing Physical Properties.

2 DS.11.187.DOF Testing Performed as Part of DURAFIBER Photo Shoot.

3 Case Series Evaluation: The Use of DURAFIBER on Exuding Wounds. Wounds UK 2012,Vol 8, No 3.

4 Smith & Nephew Wound Management Laboratory Report Reference DS/10/060/R1, DURAFIBER Ag Dressing Physical Properties, Dowler A, September 2010.

5 Smith & Nephew Wound Management, Data on File Report Reference OR- DOF/28, A prospective, open, multicentre study to evaluate a new fibrous silver dressing in the treatment of moderate to highly exuding chronic wounds, Rafiq G, Fenton S January 2013.

6 Smith & Nephew Wound Management Laboratory Report Reference DS/12/093/DOF, Integrity Testing of DURAFIBER Ag in horse serum and ionic solution, Dowler A, April 2012.

7 Smith & Nephew Wound Management Data on File 10.040.01 April 2010 Visual demonstration of sequestration of Pseudomonas aeruginosa and Staphylococcus aureus in a DURAFIBER dressing using confocal microscopy.

8 Smith & Nephew Report DS.10.042 R1 Report of testing on lateral wicking of DURAFIBER versus AquacelTM and Kaltostat TM dressings.

9 Smith & Nephew Wound Management Laboratory Report Reference DS/12/109/DOF, Testing on Absorption of DURAFIBER Ag versus Aquacel Ag during compression, Dowler A, April 2012.

10 Smith & Nephew Wound Management Laboratory Report Reference DS/12/158/DOF, Sequestration Testing of DURAFIBER Ag, Aquacel Ag and SorbsanTM Silver Flat, Dowler A,June 2012.

11 Smith & Nephew Wound Management Laboratory Report Reference DS/12/108/DOF, Testing on lateral wicking of DURAFIBER Ag versus Aquacel Ag and MaxorbTM Extra Ag dressings, Dowler A, April 2012.

12 Smith & Nephew Research Centre Review Report, The potential for proliferation of bacteria in wound exudate, Report Reference RR-WMP06290-40-01, Woodmansey E, April 2010.

13 Smith & Nephew Wound Management, Data on file report reference 1208007, Visual demonstration of sequestration of Pseudomonas aeruginosa and Staphylococcus aureus in a DURAFIBER Ag dressing using confocal microscopy. Lumb H, August 2012.

14 Smith & Nephew Wound Management, Data on file report reference 1004007, Antimicrobial activity of DURAFIBER Ag and Aquacel Ag against bacteria, yeast and fungi commonly found in wounds over a 7 day period, Woodmansey E, April 2010.

15 Smith & Nephew Wound Management, Data on file report reference 1009012, Antimicrobial activity of DURAFIBER Ag against bacteria, yeast and fungi commonly found in wounds over a 7 day period, Vaughan KL, McMillan J, Lumb H and Woodmansey E, September 2010.

16 Smith & Nephew Wound Management, Data on file report reference 1004009, Assessment of the contact kill activity of DURAFIBER Ag against common wound pathogens, Woodmansey E, April 2010.

17 Smith & Nephew Wound Management, Data on file report reference 1009013, Antimicrobial activity of DURAFIBER Ag against bacteria, yeast and fungi commonly found in wounds over a 4 hour period, Vaughan KL, McMillan J, Lumb H and Woodmansey E, September 2010.

18 World Union of Wound Healing Societies (WUWHS) Principles of best practice. Wound exudate and the role of dressings. A consensus document London MED Ltd. 2007.

19 Smith & Nephew Wound Management Laboratory Report Reference DS/12/143/DOF, Intimate Contact Testing of DURAFIBER Ag, Aquacel Ag and Sorbsan Silver Flat, Dowler A, June 2012.

20 Smith & Nephew Research Centre Review Report RR WMP06290-40-01 The potential for proliferation of bacteria in wound exudate.

21 The Clinical and Physical Properties of DURAFIBER Ag, the Moist Wound Environment and the Autolytic Debridement, Myers D, July 2012.

22 Smith & Nephew Report DS.10.013 R1 02 2010 Aquacel Dressing Physical Properties.

23 Smith & Nephew Wound Management Laboratory Report Reference DS/10/060/R2, Aquacel Ag Dressing Physical Properties.

24 NHS Drug Tariff August 2012 http://www.ppa.org.uk/ppa/edit_intro.htm

25 Unit costs of health and social care, Curtis, L. PSSRU: 2010.

26 Siddiqui AR, Bernstein JM (2010).

27 DURAFIBER Technology video

28 Smith & Nephew Report DS/12/314 R December 2012 Wound Model Testing of DURAFIBER with various secondary dressings

29 DURAFIBER SMTL report 3303 Wound Dressing Testing

30 Smith & Nephew Report Development Services, Analytical Report Reference DS/10/053/R1, Wound Model Testing of DURFAIBER Ag and Aquacel Ag dressings with various secondary dressings, Dowler A, August 2010.

*In comparison with standard Aquacel dressings, excludes Aquacel Ribbon with strengthening fibre and Aquacel Extra

**In comparison with standard Aquacel Ag dressings, excludes Aquacel Ag Ribbon with strengthening fibre and Aquacel Ag Extra

Aquacel is a trademark of Convatec

TM All trademarks acknowledged

References relate to in vitro testing excluding references 3,5,18,21,24,25,26

Ofte stillede spørgsmål

DURAFIBER

Hvilken type sår kan DURAFIBER anvendes til?

DURAFIBER kan anvendes til behandling af kroniske og akutte sår, overfladiske og dybe, granulerende sår som: bensår, tryksår, diabetessår, delhudsbrandsår, donorsteder, kirurgiske sår og traumesår, sekundær sårheling og sår, der har tendens til at bløde let efter oprensning. BEMÆRK: DURAFIBER er ikke beregnet til at blive anvendt som en kirurgisk svamp.

Hvor ofte skal DURAFIBER skiftes?

DURAFIBER kan sidde på i op til 7 dage, idet de meget absorberende egenskaber hjælper med til at kontrollere væsken effektivt. Alternativt skal den skiftes ved klinisk indikation, f.eks., hvis der er kraftigt ekssudat eller lækage.

I hvilke størrelser fås DURAFIBER?

DURAFIBER fås i følgende størrelser - a) firkantet: 5 x 5 cm, 10 x 10 cm, 15 x 15 cm, b) rektangulær: 4 x 10 cm, 4 x 20 cm, 4 x 30 cm og c) strimmel: 2 x 45 cm

Hvordan er DURAFIBER steriliseret?

DURAFIBER er gammabestrålet.

Hvordan er DURAFIBER emballeret?

DURAFIBER er emballeret i polypapirpakker.

Hvordan adskiller DURAFIBERs konstruktion sig fra Aquacel™* ?

Med hensyn til de to produkters sammensætning består både DURAFIBER og Aquacel af 100 % cellulosebaserede fibre. Forskellen mellem de to produkter består i den måde, hvorpå disse fibre modificeres, så de danner en bandage med gelerende og absorberende egenskaber.  Convatec modificerer cellulosefibrene vha. carboxymethylering for at danne en carboxymethylcellulose (CMC) -baseret bandage, som er i stand til at transformere sig til en gel og absorbere ekssudat.
Convatec have intellectual property protection that prevents other manufacturers from using CMC fibres in wound dressings of this type. With DURAFIBER, Smith & Nephew have developed an alternative way of modifiying the base cellulose fibres, namely ethyl sulphonation. This process produces a cellulose ethyl sulphonate (CES) based dressing which is similarly capable of transforming into a

Virker DURAFIBER på samme måde som Aquacel*?

DURAFIBER er en non-woven, gelerende fiberbandage, som er designet til at give tilsvarende ydelse som Aquacel med det resultat, at den danner en blød, sammenhængende gel ved kontakt med væske, former sig efter sårbunden, indkapsler absorberet væske og bakterier og forhindrer den laterale spredning af væske og minimerer således risikoen for maceration omkring såret 1,2,7,8

Hvilke fordele har DURAFIBER sammenlignet med Aquacel?

Sammenlignet med standard Aquacel er DURAFIBER også designet til at yde mere end tre og en halv gang bedre styrke i våd tilstand – geleret styrke er vigtig for nemt at kunne fjerne bandagen i ét stykke 1,2,22, over 30 % bedre absorptionsevne – bandageabsorptionsevne er vigtigt for at sikre effektiv væskekontrol 1,2,22 og 43 % mindre bandagekrympning – minimal krympning er vigtigt for at opnå vedvarende dækning af sårbunden 1,2,22

Findes der oplysninger, der viser produktets ydelse sammenlignet med Aquacel*?

DURAFIBER's fysiske egenskaber og standard Aquacel er blevet sammenlignet in-vitro af Smith & Nephew og af et uafhængigt testinstitut, SMTL. Resultaterne viser tydeligt, at de to bandager har lignende ydelsesegenskaber uanset forskellene i den kemiske modifikationsproces 1,2,22. Disse resultater viser også, at DURAFIBER har bedre styrke i våd tilstand 1,2,22,29, højere absorptionsevne 1,2,22 og reduceret bandagekrympning 1,2,22 sammenlignet med standard Aquacel.

 

DURAFIBER AgHyppigt stillede spørgsmål om DURAFIBER Ag-bandager

Hvilken type sår kan DURAFIBER Ag anvendes til?

DURAFIBER Ag kan anvendes til behandling af kroniske og akutte sår, overfladiske, granulerende og væskende sår. For eksempel: bensår, tryksår, diabetessår, kirurgiske sår, traumatiske sår, donorsteder, delhudsbrandsår, kavitet- og fistelsår, sekundært helende sår, og sår der har tendens til at bløde, samt sår, der er blevet kirurgisk eller mekanisk oprenset.

Hvor ofte skal DURAFIBER Ag skiftes?

DURAFIBER Ag kan forblive på plads i op til 7 dage, da dens meget absorberende egenskab hjælper med til at kontrollere væsken effektivt. Alternativt skal den skiftes ved klinisk indikation, f.eks., hvis der er kraftigt ekssudat til stede eller lækage.

I hvilke størrelser fås DURAFIBER Ag?

DURAFIBER fås i følgende størrelser - a) firkantet: 5 x 5 cm, 10 x 10 cm, 15 x 15 cm, b) rektangulært: 20 x 30 cm, 4 x10 cm, 4 x 20 cm, 4 x 30 cm og c) strimmel: 2 x 45 cm

Hvordan er DURAFIBER Ag steriliseret?

DURAFIBER er gammabestrålet.

Hvordan er DURAFIBER Ag emballeret?

DURAFIBER er emballeret i folie

Hvilke fordele har DURAFIBER Ag sammenlignet med Aquacel Ag**?

Sammenlignet med standard Aquacel Ag er DURAFIBER Ag også designet til at yde mere end tre og en halv gang bedre styrke i våd tilstand – geleret styrke er vigtig for nemt at kunne fjerne bandagen i ét stykke, over 17 % bedre absorptionsevne – bandageabsorptionsevne er vigtigt for at sikre effektiv væskekontrol og 43 % mindre bandagekrympning – minimal krympning er vigtigt for at opnå vedvarende dækning af sårbunden

Findes der oplysninger, der viser produktets ydelse (in vitro) sammenlignet med Aquacel Ag**?

De fysiske egenskaber hos DURAFIBER Ag og standard Aquacel Ag er blevet sammenlignet (in vitro) af Smith & Nephew. Resultaterne viser tydeligt, at de to bandager har lignende ydelsesegenskaber uanset forskellene i den kemiske modifikationsproces. Disse resultater viser også, at DURAFIBER Ag har bedre styrke i våd tilstand, højere absorptionsevne og reduceret bandagekrympning sammenlignet med standard Aquacel Ag. DURAFIBER Ag har en antimikrobiel virkning, der svarer til Aquacel Ag's.

Hvilken type sølv indeholder DURAFIBER Ag?

Bandagen indeholder sølvchlorid, som opløses i sølvioner, der afgives i såret. 




References

1 Smith & Nephew Report DS.10.056 R1 05 2010 DURAFIBER Dressing Physical Properties.

2 DS.11.187.DOF Testing Performed as Part of DURAFIBER Photo Shoot.

3 Case Series Evaluation: The Use of DURAFIBER on Exuding Wounds. Wounds UK 2012,Vol 8, No 3.

4 Smith & Nephew Wound Management Laboratory Report Reference DS/10/060/R1, DURAFIBER Ag Dressing Physical Properties, Dowler A, September 2010.

5 Smith & Nephew Wound Management, Data on File Report Reference OR- DOF/28, A prospective, open, multicentre study to evaluate a new fibrous silver dressing in the treatment of moderate to highly exuding chronic wounds, Rafiq G, Fenton S January 2013.

6 Smith & Nephew Wound Management Laboratory Report Reference DS/12/093/DOF, Integrity Testing of DURAFIBER Ag in horse serum and ionic solution, Dowler A, April 2012.

7 Smith & Nephew Wound Management Data on File 10.040.01 April 2010 Visual demonstration of sequestration of Pseudomonas aeruginosa and Staphylococcus aureus in a DURAFIBER dressing using confocal microscopy.

8 Smith & Nephew Report DS.10.042 R1 Report of testing on lateral wicking of DURAFIBER versus AquacelTM and Kaltostat TM dressings.

9 Smith & Nephew Wound Management Laboratory Report Reference DS/12/109/DOF, Testing on Absorption of DURAFIBER Ag versus Aquacel Ag during compression, Dowler A, April 2012.

10 Smith & Nephew Wound Management Laboratory Report Reference DS/12/158/DOF, Sequestration Testing of DURAFIBER Ag, Aquacel Ag and SorbsanTM Silver Flat, Dowler A,June 2012.

11 Smith & Nephew Wound Management Laboratory Report Reference DS/12/108/DOF, Testing on lateral wicking of DURAFIBER Ag versus Aquacel Ag and MaxorbTM Extra Ag dressings, Dowler A, April 2012.

12 Smith & Nephew Research Centre Review Report, The potential for proliferation of bacteria in wound exudate, Report Reference RR-WMP06290-40-01, Woodmansey E, April 2010.

13 Smith & Nephew Wound Management, Data on file report reference 1208007, Visual demonstration of sequestration of Pseudomonas aeruginosa and Staphylococcus aureus in a DURAFIBER Ag dressing using confocal microscopy. Lumb H, August 2012.

14 Smith & Nephew Wound Management, Data on file report reference 1004007, Antimicrobial activity of DURAFIBER Ag and Aquacel Ag against bacteria, yeast and fungi commonly found in wounds over a 7 day period, Woodmansey E, April 2010.

15 Smith & Nephew Wound Management, Data on file report reference 1009012, Antimicrobial activity of DURAFIBER Ag against bacteria, yeast and fungi commonly found in wounds over a 7 day period, Vaughan KL, McMillan J, Lumb H and Woodmansey E, September 2010.

16 Smith & Nephew Wound Management, Data on file report reference 1004009, Assessment of the contact kill activity of DURAFIBER Ag against common wound pathogens, Woodmansey E, April 2010.

17 Smith & Nephew Wound Management, Data on file report reference 1009013, Antimicrobial activity of DURAFIBER Ag against bacteria, yeast and fungi commonly found in wounds over a 4 hour period, Vaughan KL, McMillan J, Lumb H and Woodmansey E, September 2010.

18 World Union of Wound Healing Societies (WUWHS) Principles of best practice. Wound exudate and the role of dressings. A consensus document London MED Ltd. 2007.

19 Smith & Nephew Wound Management Laboratory Report Reference DS/12/143/DOF, Intimate Contact Testing of DURAFIBER Ag, Aquacel Ag and Sorbsan Silver Flat, Dowler A, June 2012.

20 Smith & Nephew Research Centre Review Report RR WMP06290-40-01 The potential for proliferation of bacteria in wound exudate.

21 The Clinical and Physical Properties of DURAFIBER Ag, the Moist Wound Environment and the Autolytic Debridement, Myers D, July 2012.

22 Smith & Nephew Report DS.10.013 R1 02 2010 Aquacel Dressing Physical Properties.

23 Smith & Nephew Wound Management Laboratory Report Reference DS/10/060/R2, Aquacel Ag Dressing Physical Properties.

24 NHS Drug Tariff August 2012 http://www.ppa.org.uk/ppa/edit_intro.htm

25 Unit costs of health and social care, Curtis, L. PSSRU: 2010.

26 Siddiqui AR, Bernstein JM (2010).

27 DURAFIBER Technology video

28 Smith & Nephew Report DS/12/314 R December 2012 Wound Model Testing of DURAFIBER with various secondary dressings

29 DURAFIBER SMTL report 3303 Wound Dressing Testing

30 Smith & Nephew Report Development Services, Analytical Report Reference DS/10/053/R1, Wound Model Testing of DURFAIBER Ag and Aquacel Ag dressings with various secondary dressings, Dowler A, August 2010.

*In comparison with standard Aquacel dressings, excludes Aquacel Ribbon with strengthening fibre and Aquacel Extra

**In comparison with standard Aquacel Ag dressings, excludes Aquacel Ag Ribbon with strengthening fibre and Aquacel Ag Extra

Aquacel is a trademark of Convatec

TM All trademarks acknowledged

References relate to in vitro testing excluding references 3,5,18,21,24,25,26

DURAFIBER

En ny generation af stærke, non woven, gelerende fiberbandager

Kan fjernes i ét stykke.

Læs mere

DURAFIBER Ag

En absorberende, non-woven, sølvholdig antimikrobiel bandage, der er sammensat af celluloseetylsulfonat fibre.

Contact Us

DURAFIBER RangeDiscover more about the DURAFIBER range Enquiry Form

Get in Touch

This information is intended for Healthcare Professionals only.